A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Altor BioScience
Altor BioScience
ImmunityBio, Inc.
ImmunityBio, Inc.
Altor BioScience
Altor BioScience
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
NantCell, Inc.
ImmunityBio, Inc.
Altor BioScience
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.
ImmunityBio, Inc.